{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:06:40Z","timestamp":1790226400287,"version":"4.1.0"},"reference-count":201,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ogc.2013.05.009","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T21:45:35Z","timestamp":1375220735000},"page":"475-512","source":"Crossref","is-referenced-by-count":11,"title":["Hereditary Breast\/Ovarian Cancer Syndrome"],"prefix":"10.1016","volume":"40","author":[{"given":"Dana","family":"Meaney-Delman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia A.","family":"Bellcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib2","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","article-title":"The genetic attributable risk of breast and ovarian cancer","volume":"77","author":"Claus","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ogc.2013.05.009_bib3","series-title":"The genetics of breast cancer","author":"Rubinstein","year":"2001"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/PPO.0b013e31826246c2","article-title":"Genetic testing by cancer site: ovary","volume":"18","author":"Weissman","year":"2012","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/GCO.0b013e328332dca3","article-title":"BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications","volume":"22","author":"Kurian","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ogc.2013.05.009_bib6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ogc.2013.05.009_bib7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ogc.2013.05.009_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group","volume":"83","author":"Group ABCS","year":"2000","journal-title":"Br J Cancer"},{"issue":"5182","key":"10.1016\/j.ogc.2013.05.009_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.ogc.2013.05.009_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force","volume":"143","author":"Nelson","year":"2005","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"25","key":"10.1016\/j.ogc.2013.05.009_bib14","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-143-5-200509060-00011","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement","volume":"143","author":"U.S. Preventive Services Task Force","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","article-title":"ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome","volume":"113","author":"American College of Obstetricians and Gynecologists","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ogc.2013.05.009_bib22","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Genetic\/familial high-risk assessment: breast and ovarian. 2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf. Accessed March 1, 2013."},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/cncr.22202","article-title":"Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening","volume":"107","author":"Hoskins","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1245\/s10434-009-0697-9","article-title":"Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations","volume":"17","author":"Teller","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/GIM.0b013e3181d4bc3a","article-title":"Further development and evaluation of a breast\/ovarian cancer genetics referral screening tool","volume":"12","author":"Bellcross","year":"2010","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/GIM.0b013e3181b9b04a","article-title":"Evaluation of a breast\/ovarian cancer genetics referral screening tool in a mammography population","volume":"11","author":"Bellcross","year":"2009","journal-title":"Genet Med"},{"issue":"24","key":"10.1016\/j.ogc.2013.05.009_bib27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ogc.2013.05.009_bib28","unstructured":"Cancer Co. Cancer Program Standards 2012: ensuring patient-centered care. 2012; V1.1. Available at: http:\/\/www.facs.org\/cancer\/coc\/programstandards2012.pdf. Accessed March 1, 2012."},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10897-012-9547-1","article-title":"NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer","volume":"22","author":"Berliner","year":"2013","journal-title":"J\u00a0Genet Couns"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10897-011-9462-x","article-title":"Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors","volume":"21","author":"Riley","year":"2012","journal-title":"J\u00a0Genet Couns"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"28","author":"Robson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9738","key":"10.1016\/j.ogc.2013.05.009_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(10)61150-6","article-title":"The double-helix derailed: the story of the BRCA patent","volume":"376","author":"Matloff","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-009-0611-y","article-title":"Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2","volume":"119","author":"Domchek","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"10.1016\/j.ogc.2013.05.009_bib34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/jnci\/dji281","article-title":"Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families","volume":"97","author":"Kauff","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PPO.0b013e318260946f","article-title":"Genetic testing by cancer site: breast","volume":"18","author":"Shannon","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.ogc.2013.05.009_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3322\/caac.20128","article-title":"Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine","volume":"61","author":"Weitzel","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10911-011-9213-5","article-title":"Inherited mutations in breast cancer genes\u2013risk and response","volume":"16","author":"Shuen","year":"2011","journal-title":"J\u00a0Mammary Gland Biol Neoplasia"},{"issue":"17","key":"10.1016\/j.ogc.2013.05.009_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3000214","article-title":"Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: the problem of misattributed equivalence","volume":"2","author":"Eng","year":"2010","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa0907727","article-title":"Performance of common genetic variants in breast-cancer risk models","volume":"362","author":"Wacholder","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ogc.2013.05.009_bib41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/annonc\/mdn527","article-title":"Age of onset in familial cancer","volume":"19","author":"Brandt","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ogc.2013.05.009_bib42","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1111\/j.1524-4741.2009.00798.x","article-title":"Influence of race\/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer","volume":"15","author":"Forman","year":"2009","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/gte.2006.9999","article-title":"The role of financial factors in acceptance of clinical BRCA genetic testing","volume":"11","author":"Kieran","year":"2007","journal-title":"Genet Test"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/GIM.0b013e3181837246","article-title":"Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians","volume":"10","author":"Lowstuter","year":"2008","journal-title":"Genet Med"},{"issue":"39","key":"10.1016\/j.ogc.2013.05.009_bib45","first-page":"1348","article-title":"Health plan implementation of U.S. Preventive Services Task Force A and B recommendations\u2013Colorado, 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ogc.2013.05.009_bib46","unstructured":"Institute NHGR. Genetic discrimination. Available at: http:\/\/www.genome.gov\/10002077. Accessed March 1, 2013."},{"key":"10.1016\/j.ogc.2013.05.009_bib47","first-page":"1","article-title":"The Affordable Care Act's pre-existing condition insurance plan: enrollment, costs, and lessons for reform","volume":"24","author":"Hall","year":"2012","journal-title":"Issue Brief (Commonw Fund)"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1037\/a0014778","article-title":"Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","volume":"28","author":"Hamilton","year":"2009","journal-title":"Health Psychol"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib49","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.1998.16.5.1650","article-title":"What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing","volume":"16","author":"Lerman","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cancergencyto.2005.07.011","article-title":"Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families","volume":"165","author":"Lynch","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cncr.26284","article-title":"Earlier age of onset of BRCA mutation-related cancers in subsequent generations","volume":"118","author":"Litton","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib52","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib54","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1188\/10.ONF.627-634","article-title":"Conditions and consequences of a BRCA mutation in young, single women of childbearing age","volume":"37","author":"Hamilton","year":"2010","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib56","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib57","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/humrep\/des441","article-title":"Reproductive decision-making in young female carriers of a BRCA mutation","volume":"28","author":"Donnelly","year":"2013","journal-title":"Hum Reprod"},{"issue":"7","key":"10.1016\/j.ogc.2013.05.009_bib58","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1055-9965.EPI-12-0149","article-title":"A\u00a0simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers","volume":"21","author":"Sigal","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10689-012-9577-8","article-title":"Feasibility evaluation of an online tool to guide decisions for BRCA1\/2 mutation carriers","volume":"12","author":"Schackmann","year":"2013","journal-title":"Fam Cancer"},{"issue":"18","key":"10.1016\/j.ogc.2013.05.009_bib60","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ogc.2013.05.009_bib61","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.ogc.2013.05.009_bib62","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.2011.678","article-title":"Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer","volume":"305","author":"Tung","year":"2011","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1016\/j.ogc.2013.05.009_bib63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1245\/s10434-010-1259-x","article-title":"Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer","volume":"17","author":"Stucky","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1054\/bjoc.2000.1239","article-title":"Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer","volume":"83","author":"Verhoog","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semradonc.2010.08.008","article-title":"Radiotherapy in the treatment of hereditary breast cancer","volume":"21","author":"Pierce","year":"2011","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-010-0769-3","article-title":"Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer","volume":"123","author":"Reding","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib67","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","article-title":"Cancer risks among BRCA1 and BRCA2 mutation carriers","volume":"96","author":"Levy-Lahad","year":"2007","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ogc.2013.05.009_bib70","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0511301103","article-title":"Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population","volume":"103","author":"Simchoni","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib71","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/522611","article-title":"RAD51 135G\u2013>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies","volume":"81","author":"Antoniou","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"24","key":"10.1016\/j.ogc.2013.05.009_bib72","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","volume":"102","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib73","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10552-005-1724-1","article-title":"Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"16","author":"Kotsopoulos","year":"2005","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.ejhg.5200755","article-title":"BRCA mutations in Italian breast\/ovarian cancer families","volume":"10","author":"Nedelcu","year":"2002","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib75","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.21273","article-title":"Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers","volume":"117","author":"Cullinane","year":"2005","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib76","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr3138","article-title":"Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"14","author":"Kotsopoulos","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib77","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jnci\/djj132","article-title":"Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1\/2 Carrier Cohort Study (IBCCS)","volume":"98","author":"Andrieu","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5645","key":"10.1016\/j.ogc.2013.05.009_bib79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib80","doi-asserted-by":"crossref","first-page":"R833","DOI":"10.1186\/bcr1293","article-title":"Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"7","author":"Kotsopoulos","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib81","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.ogc.2013.05.009_bib82","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib83","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","article-title":"A\u00a0combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment","volume":"6","author":"Robson","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib85","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","article-title":"Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases","volume":"43","author":"Brekelmans","year":"2007","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","article-title":"Prognosis of BRCA-associated breast cancer: a summary of evidence","volume":"119","author":"Bordeleau","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib88","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.ogc.2013.05.009_bib89","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pec.2012.03.019","article-title":"Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact","volume":"89","author":"Wevers","year":"2012","journal-title":"Patient Educ Couns"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib91","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1245\/s10434-012-2299-1","article-title":"Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients","volume":"19","author":"Chung","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.ogc.2013.05.009_bib93","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1001\/jama.2010.1854","article-title":"Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers","volume":"304","author":"Heemskerk-Gerritsen","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib94","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"van Sprundel","year":"2005","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.ogc.2013.05.009_bib95","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2008.19.9067","article-title":"Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Kriege","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9737","key":"10.1016\/j.ogc.2013.05.009_bib96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib97","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.ogc.2013.05.009_bib98","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1200\/JCO.2004.00.4960","article-title":"Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer","volume":"23","author":"Kuhl","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib99","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cncr.26424","article-title":"Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis","volume":"118","author":"Lowry","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.ogc.2013.05.009_bib101","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib102","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/cncr.27864","article-title":"Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers","volume":"119","author":"Cott Chubiz","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition","volume":"351","author":"Kriege","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9473","key":"10.1016\/j.ogc.2013.05.009_bib104","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","article-title":"Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)","volume":"365","author":"Leach","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-006-9230-z","article-title":"Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer","volume":"100","author":"Kriege","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib106","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib107","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMcp071286","article-title":"Clinical practice. Management of an inherited predisposition to breast cancer","volume":"357","author":"Robson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib108","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ogc.2013.05.009_bib109","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib112","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"issue":"30","key":"10.1016\/j.ogc.2013.05.009_bib113","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib114","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ogc.2013.05.009_bib116","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ogc.2013.05.009_bib117","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib118","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib119","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10689-005-4215-3","article-title":"The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation","volume":"4","author":"Metcalfe","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ogc.2013.05.009_bib120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-642-10858-7_13","article-title":"Chemoprevention of hormone receptor-negative breast cancer: new approaches needed","volume":"188","author":"Uray","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib121","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/CCO.0b013e3283499da9","article-title":"Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies","volume":"23","author":"Long","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"22","key":"10.1016\/j.ogc.2013.05.009_bib122","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib123","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J","article-title":"Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry","volume":"71","author":"Piver","year":"1993","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib124","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","article-title":"Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers","volume":"46","author":"Evans","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ogc.2007.10.001","article-title":"Strategies for ovarian cancer prevention","volume":"34","author":"Dann","year":"2007","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"7","key":"10.1016\/j.ogc.2013.05.009_bib126","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ogc.2013.05.009_bib127","first-page":"2433","article-title":"Frequency of germline and somatic BRCA1 mutations in ovarian cancer","volume":"4","author":"Berchuck","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib129","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2009.89","article-title":"Candidate serous cancer precursors in fallopian tube epithelium of BRCA1\/2 mutation carriers","volume":"22","author":"Shaw","year":"2009","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/gyno.2000.6095","article-title":"A\u00a0genetic epidemiological study of carcinoma of the fallopian tube","volume":"80","author":"Aziz","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ogc.2013.05.009_bib131","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib132","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib133","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib134","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2010.12.354","article-title":"Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations","volume":"121","author":"Lacour","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"34","key":"10.1016\/j.ogc.2013.05.009_bib135","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ogc.2013.05.009_bib136","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1002\/cncr.26655","article-title":"Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer","volume":"118","author":"Hyman","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ogc.2013.05.009_bib137","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2217\/pgs.12.137","article-title":"Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer","volume":"13","author":"Liu","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"15","key":"10.1016\/j.ogc.2013.05.009_bib138","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib139","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ygyno.2011.12.415","article-title":"Hereditary ovarian cancer: beyond the usual suspects","volume":"124","author":"Pennington","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib141","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1517\/13543784.2013.772135","article-title":"A\u00a0review of iniparib in ovarian cancer","volume":"22","author":"Wilkinson-Ryan","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib142","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/CCO.0b013e3283564230","article-title":"Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer","volume":"24","author":"Ratner","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"10.1016\/j.ogc.2013.05.009_bib143","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","article-title":"Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective","volume":"114","author":"Woodward","year":"2007","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib144","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","article-title":"Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?","volume":"124","author":"van der Velde","year":"2009","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJMcp0901926","article-title":"Clinical practice. Screening for ovarian cancer","volume":"361","author":"Clarke-Pearson","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ogc.2013.05.009_bib146","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib147","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00404-010-1476-3","article-title":"Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers","volume":"283","author":"Rhiem","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib148","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.maturitas.2010.03.018","article-title":"Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers","volume":"66","author":"Kenkhuis","year":"2010","journal-title":"Maturitas"},{"issue":"14","key":"10.1016\/j.ogc.2013.05.009_bib149","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","article-title":"Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy","volume":"18","author":"Lu","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"issue":"31","key":"10.1016\/j.ogc.2013.05.009_bib151","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib152","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","article-title":"Pathologic findings in prophylactic oophorectomy specimens in high-risk women","volume":"87","author":"Leeper","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib153","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib154","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2012.06.015","article-title":"Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls","volume":"127","author":"Mingels","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000478-200202000-00003","article-title":"Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up","volume":"26","author":"Agoff","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib156","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ygyno.2012.03.009","article-title":"Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility","volume":"125","author":"Landon","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1016\/j.ogc.2013.05.009_bib157","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib158","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib159","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pon.2041","article-title":"The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation","volume":"22","author":"Finch","year":"2013","journal-title":"Psychooncology"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2217\/whe.12.41","article-title":"BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations","volume":"8","author":"Finch","year":"2012","journal-title":"Womens Health (Lond Engl)"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib161","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.maturitas.2011.08.001","article-title":"Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review","volume":"70","author":"Finch","year":"2011","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib162","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10689-010-9384-z","article-title":"What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy","volume":"10","author":"Campfield Bonadies","year":"2011","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib163","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10689-011-9480-8","article-title":"Non-cancer endpoints in BRCA1\/2 carriers after risk-reducing salpingo-oophorectomy","volume":"11","author":"Cohen","year":"2012","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib164","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/bjc.2011.202","article-title":"Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT","volume":"105","author":"Challberg","year":"2011","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib165","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/archinternmed.2011.121","article-title":"Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study","volume":"171","author":"Jacoby","year":"2011","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ogc.2013.05.009_bib166","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/gme.0b013e318239caeb","article-title":"Surgical menopause and nonvertebral fracture risk among older US women","volume":"19","author":"Vesco","year":"2012","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib167","doi-asserted-by":"crossref","first-page":"e1000181","DOI":"10.1371\/journal.pmed.1000181","article-title":"Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis","volume":"6","author":"Banks","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib168","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"18","key":"10.1016\/j.ogc.2013.05.009_bib169","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198704303161801","article-title":"Menopause and the risk of coronary heart disease in women","volume":"316","author":"Colditz","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.gme.0000218683.97338.ea","article-title":"Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis","volume":"13","author":"Atsma","year":"2006","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib171","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib172","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0002-9378(99)70663-0","article-title":"Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening","volume":"180","author":"Karlan","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib173","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib174","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10689-008-9208-6","article-title":"Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy","volume":"8","author":"Gabriel","year":"2009","journal-title":"Fam Cancer"},{"issue":"6","key":"10.1016\/j.ogc.2013.05.009_bib175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","article-title":"Breast cancer after use of estrogen plus progestin in postmenopausal women","volume":"360","author":"Chlebowski","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ogc.2013.05.009_bib176","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ogc.2013.05.009_bib177","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJM200112063452312","article-title":"Ovarian cancer, oral contraceptives, and BRCA mutations","volume":"345","author":"Narod","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ogc.2013.05.009_bib178","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3109\/09513590.2010.487609","article-title":"Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy","volume":"26","author":"Gadducci","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib179","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2010.03.014","article-title":"Hormone prevention strategies for breast, endometrial and ovarian cancers","volume":"118","author":"Rice","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib180","first-page":"146","article-title":"Oral contraceptives cut inherited cancer risk","volume":"19","year":"1998","journal-title":"Contracept Technol Update"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib181","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0889-8545(05)70169-8","article-title":"Health benefits of oral contraceptives","volume":"27","author":"Jensen","year":"2000","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"11","key":"10.1016\/j.ogc.2013.05.009_bib182","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","article-title":"Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations","volume":"91","author":"Whittemore","year":"2004","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ogc.2013.05.009_bib183","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib184","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/AOG.0b013e3182783c2f","article-title":"Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers","volume":"121","author":"Kwon","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib185","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2011.02.012","article-title":"Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development","volume":"121","author":"Leblanc","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2013.05.009_bib186","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib187","first-page":"313","article-title":"Mutation analysis of BRCA1 and\u00a0BRCA2 in a male breast cancer population","volume":"60","author":"Friedman","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"23","key":"10.1016\/j.ogc.2013.05.009_bib188","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","article-title":"Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","volume":"99","author":"Tai","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib189","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","article-title":"Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","volume":"15","author":"Agalliu","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CEJ.0b013e32809b4d20","article-title":"BRCA1 mutations and prostate cancer in Poland","volume":"17","author":"Cybulski","year":"2008","journal-title":"Eur J Cancer Prev"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib191","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"van Asperen","year":"2005","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib192","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10689-008-9220-x","article-title":"Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations","volume":"8","author":"Kim","year":"2009","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib193","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cancergencyto.2004.01.032","article-title":"BRCA1 and pancreatic cancer: pedigree findings and their causal relationships","volume":"158","author":"Lynch","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib194","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng0596-123","article-title":"BRCA2 germline mutations in male breast cancer cases and breast cancer families","volume":"13","author":"Couch","year":"1996","journal-title":"Nat Genet"},{"issue":"9510","key":"10.1016\/j.ogc.2013.05.009_bib195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(06)68226-3","article-title":"Male breast cancer","volume":"367","author":"Fentiman","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ogc.2013.05.009_bib196","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.ogc.2013.05.009_bib197","first-page":"3789","article-title":"Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%","volume":"62","author":"Murphy","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ogc.2013.05.009_bib198","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","article-title":"BRCA mutations and risk of prostate cancer in Ashkenazi Jews","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ogc.2013.05.009_bib199","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng0597-17","article-title":"Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients","volume":"16","author":"Ozcelik","year":"1997","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.ogc.2013.05.009_bib200","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium","volume":"91","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ogc.2013.05.009_bib201","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.suc.2013.01.005","article-title":"Genetic predisposition syndromes and their management","volume":"93","author":"Euhus","year":"2013","journal-title":"Surg Clin North Am"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854513000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854513000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T18:32:21Z","timestamp":1715797941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854513000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":201,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0889854513000557"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2013.05.009","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}